Overview of immunotherapy in Alzheimer's Disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD

Current Alzheimer Research

Volumn 11, Issue 7, 2014, Pages 623-625

  Counts, Scott E ^a   Lahiri, Debomoy K ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; IMMUNOGLOBULIN; AMPA RECEPTOR; AMYLOID BETA PROTEIN ANTIBODY; IMMUNOGLOBULIN G; NEUROPROTECTIVE AGENT; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AUTOIMMUNITY; COGNITIVE DEFECT; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); IMMUNIZATION; IMMUNOLOGY; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS, INTRAVENOUS; NEUROPROTECTIVE AGENTS; TAU PROTEINS;

EID: 84906904664     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720501107140815102453     Document Type: Editorial

References (31)

1. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57: 801-5 (2001).
2. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum antiamyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 37: 943-8 (2002).
3. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-diseaselike pathology in the PDAPP mouse. Nature 400: 173-7 (1999).
4. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-7 (2002).
5. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-62 (2005).
6. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 6: 144-51 (2009).
7. Lemere CA, Maier M, Peng Y, Jiang L, Seabrook TJ. Novel Abeta immunogens: is shorter better? Curr Alzheimer Res 4: 427-36 (2007).
8. Panza F, Frisardi V, Imbimbo BP, Seripa D, Paris F, Santamato A, et al. Anti-beta-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res 8: 808-17 (2011).
9. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-33 (2014).
10. Zhang YH, Raymick J, Sarkar S, Lahiri DK, Ray B, Holtzman D, et al. Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. Curr Alzheimer Res 10: 494-506 (2013).
11. Bosch MN, Gimeno-Bayon J, Rodriguez MJ, Pugliese M, Mahy N. Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease. Curr Alzheimer Res 10: 482-93 (2013).
12. Solomon A, Akenine U, Andreasen N, Mangialasche F, Wimo A, Jelic V, et al. Practical lessons from amyloid immunotherapy trials in Alzheimer disease. Curr Alzheimer Res 9: 1126-34 (2012).
13. Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 10: 217-28 (2013).
14. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 6: 446-50 (2009).
15. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, et al. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9:397-405 (2012).
16. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8: 659-65 (2011).
17. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 158(1): 34-42 (2009).
18. Kaveri SV. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 11: 792-4 (2012).
19. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52: 253-6 (2002).
20. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 227: 167-74 (2010).
21. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol 34(1): 74-9 (2014).
22. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 7: 90 (2010).
23. Sudduth TL, Greenstein A, Wilcock DM. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Abeta in APP/PS1 mice along a different time course than anti-Abeta antibodies. J Neurosci 33: 9684-92 (2013).
24. Puli L, Tanila H, Relkin N. Intravenous immunoglobulins for Alzheimer's disease. Curr Alzheimer Res 11(7): 626-636 (2014).
25. Gong B, Levine S, Barnum SR, Pasinetti GM. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease Curr Alzheimer Res 11(7): 637-644 (2014).
26. Lahiri DK, Ray B. Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults Curr Alzheimer Res 11(7): 645-654 (2014).
27. Counts SE, Perez SE, He B, Mufson EJ. Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's Disease. Curr Alzheimer Res 11(7): 655-663 (2014).
28. Counts SE, Ray B, Mufson EJ, Perez SE, He B, Lahiri DK. Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 34(1): 80-5 (2014).
29. Joly-Amado A, Brownlow M, Pierce J, Ravipati A, Showalter E, Li Q, et al. Intraventricular human immunoglobulin distributes extensively but fails to modify amyloid in a mouse model of amyloid deposition. Curr Alzheimer Res 11(7): 664-671 (2014).
30. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener 8: 36 (2013).
31. Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34: 4260-72 (2014).